MARKET

MESO

MESO

Mesoblast
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.480
+0.020
+0.58%
Closed 16:00 05/25 EDT
OPEN
3.470
PREV CLOSE
3.460
HIGH
3.550
LOW
3.380
VOLUME
96.73K
TURNOVER
214.94K
52 WEEK HIGH
8.85
52 WEEK LOW
3.230
MARKET CAP
451.11M
P/E (TTM)
-4.5520
1D
5D
1M
3M
1Y
5Y
Perenti Global (ASX:PRN) shareholders have endured a 44% loss from investing in the stock three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Simply Wall St. · 05/09 00:15
What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry?
The big shareholder groups in Mesoblast Limited ( ASX:MSB ) have power over the company. Institutions will often hold...
Simply Wall St. · 05/06 00:40
Mesoblast reports FQ3 results
Mesoblast press release (NASDAQ:MESO): FQ3 Revenue of $2.1M (+9.4% Y/Y). Net cash usage for operating activities in the quarter was reduced by 40%, or $10.3M, to $15.5M compared with $25.8M
Seekingalpha · 04/29 06:25
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a...
GlobeNewswire · 04/29 00:35
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R. Krause, M.D. has joined its Board of Directors. Dr. Krause was f...
GlobeNewswire · 03/24 00:40
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 148% to $3.78. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit.
Benzinga · 03/09 17:11
Is Mesoblast (ASX:MSB) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 02/27 22:18
Operational Highlights and Financial Results for the Period Ended December 31, 2021
Mesoblast Prepares for Resubmission of Biologics License Application Late-Stage Clinical Pipeline Late-Stage Clinical Pipeline NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medici...
GlobeNewswire · 02/24 22:30
More
No Data
Learn about the latest financial forecast of MESO. Analyze the recent business situations of Mesoblast through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MESO stock price target is 13.50 with a high estimate of 23.00 and a low estimate of 6.50.
High23.00
Average13.50
Low6.50
Current 3.480
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 57
Institutional Holdings: 3.37M
% Owned: 2.60%
Shares Outstanding: 129.63M
TypeInstitutionsShares
Increased
5
151.73K
New
4
53.59K
Decreased
13
174.93K
Sold Out
8
180.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Swedish
Chief Executive Officer/Executive Director
Silviu Itescu
Vice Chairman/Non-Executive Independent Director
William Burns
Chief Financial Officer
Andrew Chaponnel
General Counsel
Peter Howard
Other
Justin Horst
Other
Michael Schuster
Other
Paul Simmons
Other
Geraldine Storton
Secretary
Paul Hughes
Secretary
Niva Sivakumar
Director
Philip Krause
Non-Executive Director
Eric Rose
Non-Executive Independent Director
Philip Facchina
Non-Executive Independent Director
Michael Spooner
Non-Executive Independent Director
Shawn Tomasello
No Data
No Data
About MESO
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Webull offers kinds of Mesoblast limited (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.